Sun Pharmaceutical Industries including its subsidiaries and/or associate companies have received approval from the US Food and Drug Administration (USFDA) for Infugem (gemcitabine in 0.9 per cent sodium chloride injection) 10 mg/mL, for intravenous use in a ready-to-administer (RTA) bag.